The article discusses the development of antiviral protein–protein interaction inhibitors, focusing on their importance in combating various viruses, including HIV, SARS-CoV-2, HCV, Ebola, Dengue, and Chikungunya. These inhibitors, which include antibodies, peptides/peptidomimetics, and small molecules, offer alternative strategies to traditional enzyme inhibitors, especially given the high mutation rates of viruses. The review highlights the significance of targeting protein–protein interactions in viral entry and replication processes. For HIV, the entry process involves interactions between viral envelope glycoproteins and host cell receptors, and inhibitors such as antibodies (e.g., ibalizumab), peptides (e.g., enfuvirtide), and small molecules (e.g., maraviroc) have been developed. These inhibitors target various stages of the viral entry process, including preattachment, postattachment, coreceptor binding, and fusion. Antibodies like ibalizumab and bnAbs such as VRC01 and 3BNC117 have shown promise in neutralizing HIV. Peptides, including enfuvirtide and Sifuvirtide, have been developed to inhibit HIV fusion, while small molecules like maraviroc, a CCR5 antagonist, have been approved for clinical use. For SARS-CoV-2, the entry process involves the interaction between the viral spike protein and the host ACE2 receptor. Inhibitors include antibodies (e.g., P2B-2F6, bamlanivimab, bebtelovimab) and peptides that target the RBD of the spike protein. Small molecules, such as EK1 and IPB02, have been developed as fusion inhibitors. These inhibitors show high efficacy in neutralizing SARS-CoV-2 and preventing viral entry. The article emphasizes the importance of developing diverse antiviral strategies to combat the high mutation rates of viruses. Protein–protein interaction inhibitors offer a promising alternative to traditional enzyme inhibitors, with the potential to target multiple stages of the viral life cycle. The development of these inhibitors continues to be an active area of research, with ongoing clinical trials and structural studies providing insights into their mechanisms of action and potential for overcoming drug resistance.The article discusses the development of antiviral protein–protein interaction inhibitors, focusing on their importance in combating various viruses, including HIV, SARS-CoV-2, HCV, Ebola, Dengue, and Chikungunya. These inhibitors, which include antibodies, peptides/peptidomimetics, and small molecules, offer alternative strategies to traditional enzyme inhibitors, especially given the high mutation rates of viruses. The review highlights the significance of targeting protein–protein interactions in viral entry and replication processes. For HIV, the entry process involves interactions between viral envelope glycoproteins and host cell receptors, and inhibitors such as antibodies (e.g., ibalizumab), peptides (e.g., enfuvirtide), and small molecules (e.g., maraviroc) have been developed. These inhibitors target various stages of the viral entry process, including preattachment, postattachment, coreceptor binding, and fusion. Antibodies like ibalizumab and bnAbs such as VRC01 and 3BNC117 have shown promise in neutralizing HIV. Peptides, including enfuvirtide and Sifuvirtide, have been developed to inhibit HIV fusion, while small molecules like maraviroc, a CCR5 antagonist, have been approved for clinical use. For SARS-CoV-2, the entry process involves the interaction between the viral spike protein and the host ACE2 receptor. Inhibitors include antibodies (e.g., P2B-2F6, bamlanivimab, bebtelovimab) and peptides that target the RBD of the spike protein. Small molecules, such as EK1 and IPB02, have been developed as fusion inhibitors. These inhibitors show high efficacy in neutralizing SARS-CoV-2 and preventing viral entry. The article emphasizes the importance of developing diverse antiviral strategies to combat the high mutation rates of viruses. Protein–protein interaction inhibitors offer a promising alternative to traditional enzyme inhibitors, with the potential to target multiple stages of the viral life cycle. The development of these inhibitors continues to be an active area of research, with ongoing clinical trials and structural studies providing insights into their mechanisms of action and potential for overcoming drug resistance.